Reliable biomarkers for early detection of hepatocellular carcinoma (HCC) in patients with cirrhosis are lacking. We evaluated the use of miR-122, alpha-fetoprotein (AFP) and protein induced by vitamin k absence/antagonist II (PIVKA-II) for HCC risk prediction in patients with HBV-related cirrhosis under surveillance.
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II
Caviglia, Gian P;Abate, Maria L;Olivero, Antonella;Rosso, Chiara;Ciancio, Alessia;Saracco, Giorgio M;Smedile, Antonina
2017-01-01
Abstract
Reliable biomarkers for early detection of hepatocellular carcinoma (HCC) in patients with cirrhosis are lacking. We evaluated the use of miR-122, alpha-fetoprotein (AFP) and protein induced by vitamin k absence/antagonist II (PIVKA-II) for HCC risk prediction in patients with HBV-related cirrhosis under surveillance.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Paper_HCC Biomarkers_IRIS.doc
Accesso riservato
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
255 kB
Formato
Microsoft Word
|
255 kB | Microsoft Word | Visualizza/Apri Richiedi una copia |
|
Paper_HCC Biomarkers_IRIS.pdf
Accesso aperto
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
228.2 kB
Formato
Adobe PDF
|
228.2 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
